GRPR and medulloblastoma: In contrast to the lack of effect of activation of GRPR on growth of medulloblastoma cell lines (DAOY, D283, ONS76), the addition (213) of a NMBR antagonist (BIM-23127) (215) to the EGFR receptor antagonist cetuximab, at a concentration where cetuximab had no effect alone, reduced the viability of medulloblastoma DAOY cells.